Ask AI
SC ICI: Data

CE

SC ICI Delivery Strategies: Supporting Clinical Data for SC Immunotherapies 

Pharmacists: 0.50 contact hour (0.05 CEUs)

Released: July 13, 2026

Expiration: January 12, 2027

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Kelly Romo, PharmD, BCOP, and Shawna Kraft, PharmD, BCOP, discuss supporting clinical data for the use of subcutaneous (SC) immune checkpoint inhibitor (ICI) formulations, efficacy and safety findings, clinical pharmacodynamics/pharmacokinetics equivalence, as well as patient quality of life and preference considerations.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Please note that Decera Clinical Education plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity, and once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your individual responses will not be shared. Thank you in advance for helping us assess the impact of this education.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with cancer do you provide care for in a typical month?

For those who practice in academic or community settings, please indicate your practice setting:

Which statement best summarizes current and emerging outcomes data for SC ICIs compared with intravenous (IV) ICI formulations in solid tumors?

Which of the following is true when coordinating SC pembrolizumab preparation, administration, and safety counseling for a patient starting first-line pembrolizumab with chemotherapy for advanced non-small-cell lung cancer (NSCLC)?